Experienced in Desmoplastic Small Round Cell Tumor

Dr. David E. Kanamori

Hematology | Oncology
Ravi Patel M D Inc
6501 Truxtun Ave, 
Bakersfield, CA 
 (202.9 mi)
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Desmoplastic Small Round Cell Tumor
Ravi Patel M D Inc
6501 Truxtun Ave, 
Bakersfield, CA 
 (202.9 mi)
OverviewInsuranceLocationsClinical Research

Overview

David Kanamori is a Hematologist and an Oncologist in Bakersfield, California. Dr. Kanamori and is rated as an Experienced provider by MediFind in the treatment of Desmoplastic Small Round Cell Tumor. His top areas of expertise are Hemosiderosis, Idiopathic Pulmonary Hemosiderosis, Agranulocytosis, and Chronic Familial Neutropenia.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Specialist in CA
Hospital Affiliations
Bakersfield Memorial Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Humana

Locations

RAVI PATEL M D INC
6501 Truxtun Ave, Bakersfield, CA 93309

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
Enrollment Status: Recruiting
Publish Date: November 01, 2023
Intervention Type: Drug
Study Drugs: Ruxolitinib Oral Tablet [Jakafi], Lenalidomide, Methylprednisolone
Study Phase: Phase 1
monarcHER: A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib Plus Trastuzumab With or Without Fulvestrant to Standard-of-Care Chemotherapy of Physician's Choice Plus Trastuzumab in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
monarcHER: A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib Plus Trastuzumab With or Without Fulvestrant to Standard-of-Care Chemotherapy of Physician's Choice Plus Trastuzumab in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Drug
Study Drugs: Abemaciclib, Trastuzumab, Fulvestrant, Standard of Care Single Agent Chemotherapy
Study Phase: Phase 2
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 21, 2024
Intervention Type: Drug
Study Drugs: Abemaciclib, Erlotinib
Study Phase: Phase 3
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 18, 2024
Intervention Type: Drug
Study Drugs: Abemaciclib, Abiraterone Acetate, Prednisone
Study Phase: Phase 2/Phase 3
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drug: Canakinumab
Study Phase: Phase 3
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2024
Intervention Type: Drug
Study Drugs: alpelisib, nab-paclitaxel
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)
Enrollment Status: Completed
Publish Date: September 16, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: June 28, 2022
Intervention Type: Drug
Study Drugs: Olaratumab, Nab-paclitaxel, Gemcitabine
Study Phase: Phase 1/Phase 2
An Observational Study to Collect and Assess Tissue Samples From Subjects With One of Three Neoplastic Conditions (ANSWer)
An Observational Study to Collect and Assess Tissue Samples From Subjects With One of Three Neoplastic Conditions (ANSWer)
Enrollment Status: Completed
Publish Date: April 05, 2022
Intervention Type: Other
View 8 Less Clinical Trials

1 Total Publications

Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumors.
Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumors.
Journal: Anti-cancer drugs
Published: March 16, 2019
Similar Doctors
Experienced in Desmoplastic Small Round Cell Tumor
Dr. Ravi Patel
Hematology | Oncology
Experienced in Desmoplastic Small Round Cell Tumor
Dr. Ravi Patel
Hematology | Oncology

Ravi Patel M D Inc

6501 Truxtun Ave, 
Bakersfield, CA 
661-322-2206
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ravi Patel is a Hematologist and an Oncologist in Bakersfield, California. Dr. Patel and is rated as an Advanced provider by MediFind in the treatment of Desmoplastic Small Round Cell Tumor. His top areas of expertise are Ampullary Cancer, Agranulocytosis, Chronic Familial Neutropenia, and Diffuse Large B-Cell Lymphoma (DLBCL).

Experienced in Desmoplastic Small Round Cell Tumor
Dr. Vikas Ghai
Hematology Oncology | Hematology | Oncology
Experienced in Desmoplastic Small Round Cell Tumor
Dr. Vikas Ghai
Hematology Oncology | Hematology | Oncology

San Joaquin Community Hospital

9602 Stockdale Hwy, 
Bakersfield, CA 
 (1.9 mi)
661-395-3000
Languages Spoken:
English
Offers Telehealth

Vikas Ghai is a Hematologist Oncology specialist and a Hematologist in Bakersfield, California. Dr. Ghai and is rated as an Advanced provider by MediFind in the treatment of Desmoplastic Small Round Cell Tumor. His top areas of expertise are Paget Disease of the Breast, Lung Cancer, Familial Colorectal Cancer, and Pleuropulmonary Blastoma.

Experienced in Desmoplastic Small Round Cell Tumor
Dr. Ricardo Salas
Hematology Oncology | Hematology | Oncology
Experienced in Desmoplastic Small Round Cell Tumor
Dr. Ricardo Salas
Hematology Oncology | Hematology | Oncology

San Joaquin Community Hospital

2615 Chester Ave, 
Bakersfield, CA 
 (3.4 mi)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ricardo Salas is a Hematologist Oncology specialist and a Hematologist in Bakersfield, California. Dr. Salas and is rated as a Distinguished provider by MediFind in the treatment of Desmoplastic Small Round Cell Tumor. His top areas of expertise are Angiosarcoma, Inflammatory Breast Cancer, Paget Disease of the Breast, and Large-Cell Immunoblastic Lymphoma.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile